Biochim Biophys Acta 1839, 112
The FDA does not approve compounded medications the same way it approves branded drugs, which is why clinical oversight and baseline health assessment are critical before starting therapy
Fully domestic supply chain no imports
Because several GLP-1 receptor agonists are already approved for Type 2 diabetes mellitus and obesity, they may reach addiction treatment settings more rapidly than newly developed drugs if clinical efficacy is proven
Clinical trials data show Wegovy users lost an average of 15% of their body weight over 68 weeks , while Mounjaro users experienced reductions of 18-21%
According to the FDA's press release it agreed to approve the drug for obesity based on three randomised, double-blind, placebo-controlled trials during which more than 2,600 patients received Wegovy for up to 68 weeks and more than 1,500 patients received placebo (US FDA 2021)